Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 1999, Versant Ventures is a prominent venture capital firm specializing in the biotechnology sector, with a robust asset under management (AUM) of $5.3 billion. The firm has built an impressive portfolio of 190 companies, achieving 131 successful exits, which underscores its strong presence in the biotech investment landscape. Versant is headquartered in the United States and has a significant focus on global markets, particularly in North America and Europe. The firm distinguishes itself through its innovative approach to venture creation, employing in-house Discovery Engines that leverage operational expertise and scientific collaboration. This hands-on methodology allows Versant to actively participate in the development of its portfolio companies from inception to growth, fostering a unique environment for innovation and success.
Versant Ventures concentrates its investments in the biotech, healthcare, and digital health sectors, targeting companies at various stages from seed to growth equity. The firm typically invests between $5 million and $50 million, allowing it to support startups with substantial capital as they scale. Versant's geographical focus spans globally, with a particular emphasis on the United States and Europe, enabling it to tap into diverse markets and innovative ecosystems. The firm seeks to partner with visionary founders and teams that are committed to advancing healthcare solutions and developing novel therapeutics. By leveraging its in-house Discovery Engines, Versant not only provides financial backing but also offers operational support and scientific expertise, making it an attractive partner for entrepreneurs in the biotech space.
Versant Ventures boasts a diverse portfolio of 190 companies, with notable investments including Jazz Pharmaceuticals, Insulet, Inari Medical, Genomic Health, and Kythera. The firm has successfully facilitated 131 exits, showcasing its ability to identify and nurture high-potential biotech ventures. Over the past year, Versant has made 25 new investments, reflecting its active engagement in the market and commitment to fostering innovation. The firm's extensive experience in the biotech sector is further highlighted by its participation in over 50 initial public offerings (IPOs) and mergers and acquisitions (M&As), solidifying its reputation as a leading player in the industry.
George G. Kauffman - Managing Partner, with extensive experience in biotech investments and a strong track record of successful exits.
Rachael H. Kauffman - Partner, focusing on healthcare investments and operational support for portfolio companies.
David L. Heller - Principal, specializing in digital health and early-stage biotech ventures.
To pitch Versant Ventures, founders should visit their website at versantventures.com. The firm prefers well-structured pitches that highlight the business model, market potential, and team qualifications. Warm introductions are beneficial, but cold applications are also accepted.
In December 2025, Versant Ventures made its latest investment, continuing its active engagement in the biotech sector. The firm has recently participated in 25 new investments over the past year, reflecting its commitment to fostering innovation and supporting emerging companies in the healthcare landscape.
Versant Ventures invests across multiple stages, including seed, Series A, Series B, Series C, and growth equity. This broad investment spectrum allows the firm to support companies at various points in their development, from early-stage startups to more established businesses seeking growth capital.
Founders interested in pitching to Versant Ventures can submit their proposals through their website at versantventures.com. The firm welcomes pitches that clearly outline the business model, market opportunity, and team background, emphasizing the innovative aspects of the venture.
Versant Ventures primarily focuses on the biotech, healthcare, and digital health sectors. The firm is particularly interested in companies that are developing novel therapeutics and innovative healthcare solutions, leveraging its deep expertise in these areas.
The typical check size for investments made by Versant Ventures ranges from $5 million to $50 million. This range allows the firm to provide substantial support to its portfolio companies as they scale and develop their products.
Versant Ventures invests globally, with a strong emphasis on the United States and Europe. This geographical focus enables the firm to tap into diverse markets and collaborate with innovative ecosystems in the biotech sector.
Versant Ventures offers extensive portfolio support through its in-house Discovery Engines, which provide operational expertise and scientific collaboration. This hands-on approach helps portfolio companies navigate challenges and accelerate their growth in the competitive biotech landscape.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.